Karen Kelly Selected Research

telisotuzumab vedotin

11/2021	Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
1/2021	A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).
11/2018	First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Karen Kelly Research Topics

Disease

74	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2022 - 02/2002
44	Neoplasms (Cancer) 04/2022 - 02/2002
28	Lung Neoplasms (Lung Cancer) 01/2022 - 02/2002
14	Disease Progression 09/2021 - 10/2007
9	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2017 - 09/2002
8	Neutropenia 10/2018 - 08/2004
5	Exanthema (Rash) 12/2020 - 05/2005
5	Fatigue 11/2018 - 08/2004
4	Carcinoma (Carcinomatosis) 01/2021 - 01/2017
4	Adenocarcinoma 01/2021 - 05/2015
4	Diarrhea 12/2020 - 12/2015
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021 - 01/2017
3	Adenocarcinoma of Lung 01/2018 - 11/2015
2	Mesothelioma 01/2021 - 07/2008
2	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 01/2019
2	Merkel Cell Carcinoma 01/2020 - 01/2017
2	Malignant Mesothelioma 10/2019 - 01/2017
2	Weight Loss (Weight Reduction) 10/2019 - 01/2015
2	Thrombocytopenia (Thrombopenia) 10/2018 - 01/2017
2	Mucositis 01/2017 - 06/2012
2	Breast Neoplasms (Breast Cancer) 02/2016 - 07/2009
2	Brain Neoplasms (Brain Tumor) 12/2015 - 08/2014
2	Febrile Neutropenia 09/2006 - 08/2004
1	Tyrosinemias (Tyrosinemia) 06/2022
1	Inborn Genetic Diseases (Disease, Hereditary) 06/2022
1	Heart Arrest (Cardiac Arrest) 01/2021
1	T-Cell Lymphoma (Lymphoma, T Cell) 10/2020

Drug/Important Bio-Agent (IBA)

17	PlatinumIBA 09/2021 - 10/2007
16	ErbB Receptors (EGF Receptor)IBA 01/2021 - 07/2003
16	Docetaxel (Taxotere)FDA Link 01/2017 - 02/2002
13	Tyrosine Kinase InhibitorsIBA 01/2022 - 07/2003
13	Cisplatin (Platino)FDA LinkGeneric 10/2019 - 02/2002
10	Biomarkers (Surrogate Marker)IBA 01/2021 - 06/2006
9	Cetuximab (Erbitux)FDA Link 01/2022 - 12/2005
9	Carboplatin (JM8)FDA LinkGeneric 01/2019 - 02/2002
9	Paclitaxel (Taxol)FDA LinkGeneric 01/2017 - 02/2002
8	Pemetrexed (MTA)FDA Link 10/2019 - 08/2004
7	avelumabIBA 04/2022 - 01/2017
6	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2013
6	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2021 - 06/2012
5	Immune Checkpoint InhibitorsIBA 01/2022 - 12/2015
5	B7-H1 AntigenIBA 01/2021 - 07/2017
5	Gefitinib (Iressa)FDA Link 05/2008 - 07/2003
4	Pharmaceutical PreparationsIBA 01/2021 - 05/2006
4	Bevacizumab (Avastin)FDA Link 01/2018 - 03/2007
4	Etoposide (VP 16)FDA LinkGeneric 09/2015 - 06/2005
4	Vinorelbine (Navelbine)FDA LinkGeneric 11/2013 - 02/2002
4	Gemcitabine FDA Link 07/2008 - 08/2004
3	trametinibIBA 02/2022 - 01/2017
3	AfatinibIBA 01/2022 - 01/2020
3	telisotuzumab vedotinIBA 11/2021 - 11/2018
3	Immunoconjugates (Immunoconjugate)IBA 11/2021 - 11/2018
3	Topotecan (Hycamtin)FDA LinkGeneric 10/2018 - 11/2006
3	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 10/2018 - 06/2005
3	Immunoglobulin G (IgG)IBA 01/2018 - 02/2016
3	Monoclonal AntibodiesIBA 01/2017 - 07/2008
3	Biological ProductsIBA 11/2015 - 02/2004
3	sulindac sulfone (exisulind)IBA 10/2007 - 02/2002
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2022 - 01/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 06/2008
2	NivolumabIBA 09/2021 - 01/2019
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2021 - 09/2002
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021 - 01/2021
2	capmatinibIBA 01/2021 - 05/2017
2	durvalumabIBA 01/2021 - 01/2021
2	Cyclin-Dependent Kinase 4IBA 12/2019 - 10/2019
2	cediranib (AZD2171)IBA 10/2019 - 01/2017
2	Angiogenesis InhibitorsIBA 10/2019 - 01/2018
2	Anaplastic Lymphoma KinaseIBA 01/2019 - 01/2014
2	Alanine Transaminase (SGPT)IBA 11/2018 - 08/2004
2	AntibodiesIBA 01/2018 - 02/2016
2	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2017 - 02/2011
2	Cytostatic AgentsIBA 10/2015 - 07/2003
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2014 - 10/2003
2	Antineoplastic Agents (Antineoplastics)IBA 05/2007 - 02/2002
1	RNA (Ribonucleic Acid)IBA 06/2022
1	BESIBA 06/2022
1	pembrolizumabIBA 01/2022
1	RamucirumabIBA 01/2022
1	IpilimumabIBA 09/2021
1	MesothelinIBA 01/2021
1	Polytetrafluoroethylene (Teflon)FDA Link 01/2021
1	veliparibIBA 01/2021
1	tremelimumabIBA 01/2021
1	Aurora KinasesIBA 01/2021
1	talazoparibIBA 01/2021
1	Immunologic Factors (Immunomodulators)IBA 01/2021
1	ABBV-428IBA 01/2021
1	MLN 8237IBA 01/2021

Therapy/Procedure

33	Drug Therapy (Chemotherapy) 01/2022 - 02/2002
31	Therapeutics 01/2022 - 02/2002
10	Immunotherapy 01/2022 - 12/2015
9	Chemoradiotherapy 01/2021 - 05/2006
8	Radiotherapy 01/2019 - 09/2006
2	Adjuvant Chemotherapy 01/2022 - 07/2005
2	Duration of Therapy 11/2020 - 07/2009
2	Combined Modality Therapy 01/2019 - 12/2005
2	Induction Chemotherapy 09/2017 - 01/2017
2	Chemoprevention 05/2009 - 02/2002
1	Lymph Node Excision (Lymph Node Dissection) 01/2022